Enveric Biosciences Announces New Preclinical Data That Further Supports The Non-Hallucinogenic Profile Of EB-003; GloSensor Assay Findings

Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay, which has been previously described in peer-reviewed scientific literature (Wang et al., 2022)1.

The Promega GloSensor™ cAMP assay is a highly sensitive live-cell test designed to detect subtle Gi-coupled receptor responses in real time.

The study evaluated EB-003 alongside known hallucinogenic and non-hallucinogenic reference compounds and produced results that the Company believes are consistent with recently published Nature research (Xu et al., 2026)2, which identified signaling characteristics that distinguish compounds predicted to be hallucinogenic from those expected to be non-hallucinogenic in humans.

The 2026 Nature paper by Xu and colleagues linked 5-HT2A receptor-mediated Gi activation with hallucinogenic compounds, suggesting that the strength of this signaling response may help predict whether a drug will be hallucinogenic in humans.

In Enveric’s study evaluations, EB-003 consistently fell within the non-hallucinogenic range.

The new findings, together with Enveric's previously reported BRET assay results, provide complementary evidence supporting Enveric's differentiated approach to developing non-hallucinogenic neuroplastogenic therapeutics.

The expanding body of preclinical evidence supports the Company's development strategy as it advances EB-003 toward a first-in-human clinical trial. "These new findings further support our previous studies regarding the differentiated design of EB-003 and its non-hallucinogenic profile," said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. "The consistency of the data across multiple independent assay platforms provides important validation of our approach as we prepare to advance EB-003 into Phase 1 clinical development.

As the FDA continues to define the regulatory framework for psychedelic-inspired therapies, we believe compounds designed to preserve the therapeutic potential of neuroplasticity without requiring a hallucinogenic experience could offer meaningful advantages in clinical development while supporting broader patient access and potential commercial adoption." The U.S.

Food and Drug Administration (FDA) recently issued final guidance outlining the unique clinical, operational and regulatory considerations associated with the development of hallucinogenic psychedelic therapies.

The guidance discusses challenges related to functional unblinding, patient monitoring, psychotherapy requirements, and trial design.

If EB-003's non-hallucinogenic profile is confirmed in human studies, Enveric believes the drug may avoid or mitigate many of these complexities, potentially enabling more conventional blinded clinical trials, a simpler outpatient treatment paradigm, and broader commercial scalability, if approved.